Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesofensine + metoprolol in hypothalamic injury-induced obesity
2018-003672-12Phase 2Completed
- Sponsor
- Saniona
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hypothalamic obesity (HO) comparing Tesofensine + metoprolol with Placebo control (2 arms). Primary endpoint: Overall safety and tolerability. Started Nov 2018; status: completed.
02
Drugs
tesofensinemetoprolol
03
Conditions
hypothalamic obesity (HO)
Beyond the preview
Go deeper on 2018-003672-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003672-12.